<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/42/299b–5" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/42/299b–5/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/42/299b–5/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_299b_5"><akn:num>299b–5</akn:num><akn:heading>Health care practice and technology innovation</akn:heading><akn:content><akn:p>§ 299b–5. Health care practice and technology innovation(a) In generalThe Director shall promote innovation in evidence-based health care practices and technologies by—(1) conducting and supporting research on the development, diffusion, and use of health care technology;

(2) developing, evaluating, and disseminating methodologies for assessments of health care practices and technologies;

(3) conducting intramural and supporting extramural assessments of existing and new health care practices and technologies;

(4) promoting education and training and providing technical assistance in the use of health care practice and technology assessment methodologies and results; and

(5) working with the National Library of Medicine and the public and private sector to develop an electronic clearinghouse of currently available assessments and those in progress.


(b) Specification of process(1) In generalNot later than December 31, 2000, the Director shall develop and publish a description of the methods used by the Agency and its contractors for health care practice and technology assessment.


(2) ConsultationsIn carrying out this subsection, the Director shall cooperate and consult with the Assistant Secretary for Health, the Administrator of the Centers for Medicare &amp; Medicaid Services, the Director of the National Institutes of Health, the Commissioner of Food and Drugs, and the heads of any other interested Federal department or agency, and shall seek input, where appropriate, from professional societies and other private and public entities.


(3) MethodologyThe Director shall, in developing the methods used under paragraph (1), consider—(A) safety, efficacy, and effectiveness;

(B) legal, social, and ethical implications;

(C) costs, benefits, and cost-effectiveness;

(D) comparisons to alternate health care practices and technologies; and

(E) requirements of Food and Drug Administration approval to avoid duplication.



(c) Specific assessments(1) In generalThe Dir</akn:p></akn:content><akn:subsection eId="subsec_299b_5_a"><akn:num>(a)</akn:num><akn:heading>In general</akn:heading><akn:content><akn:p>(a) In general The Director shall promote innovation in evidence-based health care practices and technologies by—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_299b_5_b"><akn:num>(b)</akn:num><akn:heading>Specification of process</akn:heading><akn:content><akn:p>(b) Specification of process</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_299b_5_c"><akn:num>(c)</akn:num><akn:heading>Specific assessments</akn:heading><akn:content><akn:p>(c) Specific assessments</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_299b_5_d"><akn:num>(d)</akn:num><akn:heading>Medical examination of certain victims</akn:heading><akn:content><akn:p>(d) Medical examination of certain victims</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>